General Updates | An update on the use of idasanutlin in polycythemia vera
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, gives an update on the use of idasanutlin in patients with polycythemia vera (PV). Prof. Mascarenhas first explains the rationale for using this agent to treat PV and gives an overview of the findings of clinical trials evaluating this agent. He explains that a Phase II study (NCT03287245) reported promising efficacy in patients who had been treated with previous hydroxyurea and ruxolitinib, but patients also experienced significant gastrointestinal (GI) toxicity. This interview took place virtually.
Disclosures
Research funding paid to Prof. Mascarenhas’ institution from Incyte, Novartis, Celgene, BMS, CTI Bio, Merck, Roche, Kartos, PharmaEssentia, Abbvie, and Geron. Consulting fees from Novartis, Incyte, CTI Bio, Constellation, Abbvie, Roche, Kartos, PharmaEssentia, Sierra Onc, Galecto, GSK, Karyopharm, Celgene, Geron and BMS.
